Alter Domus Launches Industry-Leading ESG Reporting Solution for Alternative Investment Managers
Alter Domus, a leading provider of integrated solutions for the alternative investment industry, today announced it has launched an industry-leading Environmental, Social & Governance (ESG) reporting solution.
Despite a lack of standardized ESG models available, demand for ESG data is booming.1 This trend has placed additional strain on alternatives managers who are increasingly fielding ESG data requests from investors, regulators, and non-governmental organizations without a clear directive on how to report or share this data.
Designed specifically for alternative assets, Alter Domus’ ESG Reporting Solution is a cloud-based digital platform that provides comprehensive, tailored reports for clients that collect, store, and disseminate corporate ESG data. Alter Domus’ ESG Reporting Solution will be accessible through an online, user-friendly portal that ensures secure access and management of client data.
Other features of Alter Domus’ ESG Reporting Solution include:
- Scoring and ratings for a fund or portfolio based on internationally recognized standards
- Data analysis that can be shared with stakeholders, including regulators for disclosure, compliance, and other reporting purposes
- Tailored benchmarking against peers and operational advisory
“Today’s announcement underscores Alter Domus’ commitment to developing and offering the most innovative products that our clients need at a global scale,” said Alex Traub, Chief Commercial Officer. “ESG has become an important part of investment philosophies for investors at every level, and we expect this trend to continue even further as ESG becomes more standardized and mainstream with alternative managers.”
“We have heard from our clients globally about the need for a standardized ESG reporting framework and solution that can be integrated across all of their operations seamlessly,” said Antonis Anastasiou, Managing Director of the Alter Domus Management Company S.A. “We worked to develop this solution that helps our clients not only navigate the complexities of ESG regulation, but to also provide their own investors with the types of reporting they need.”
For its part, and as a growing organization with an increasingly global footprint, Alter Domus ensures that ESG factors are considered as standard practice in all strategic business planning and decision making. Further, Alter Domus is a signatory of the United Nations-supported Principles for Responsible Investment, and aligned with The World Economic Forum (WEF) Measuring Stakeholder Capitalism; Towards Common Metrics and Consistent Reporting of Sustainable Value Creation framework.
Over the last 12 months, Alter Domus has seen increasing demand for alternative investments, particularly in Europe and the United States. Having doubled their assets under administration in that time, Alter Domus is at the forefront of delivering timely, technology-driven solutions to alternative asset managers, lenders, and asset owners globally.
About Alter Domus
Alter Domus is a leading provider of integrated solutions, serving private equity, real assets and debt capital markets sectors with more than 3,600 employees across 36 offices globally. Solely dedicated to alternatives, Alter Domus offers fund administration, corporate services, depositary services, capital administration, transfer pricing, domiciliation, management company services, loan administration, agency services, trade settlement and CLO manager services. Find out more at www.alterDomus.com.
1 Opimas Research: http://www.opimas.com/research/547/detail/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Marketing Content Manager
+352 661 892 226
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CARVYKTI ® (ciltacabtagene autoleucel) Granted Conditional Approval by the European Commission for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma26.5.2022 09:10:00 CEST | Press release
Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced that the European Commission (EC) has granted conditional marketing authorization of CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) for the treatment of adults with relapsed and refractory multiple myeloma (RRMM) who have received at least three prior therapies, including a proteasome inhibitor (PI), an immunomodulatory agent (IMiD) and an anti-CD38 antibody, and have demonstrated disease progression on the last therapy. Legend Biotech entered into an exclusive worldwide license and collaboration agreement with Janssen Biotech, Inc. (Janssen) to develop and commercialize cilta-cel in December 2017. CARVYKTI® is a chimeric antigen receptor T-cell (CAR-T) therapy featuring two B-cell maturation antigen (BCMA)-targeting single domain antibodies.1 CAR-T therapy is specifically developed
European Commission Grants Conditional Approval of CARVYKTI ® (Ciltacabtagene Autoleucel), Janssen’s First Cell Therapy, for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma26.5.2022 09:00:00 CEST | Press release
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the European Commission (EC) granted conditional marketing authorisation of CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) for the treatment of adults with relapsed and refractory multiple myeloma (RRMM) who have received at least three prior therapies, including an immunomodulatory agent (IMiD), a proteasome inhibitor (PI) and an anti-CD38 antibody, and have demonstrated disease progression on the last therapy. In December 2017, Janssen Biotech, Inc. (Janssen) entered into an exclusive worldwide license and collaboration agreement with Legend Biotech USA, Inc. to develop and commercialise cilta-cel.2 “Patients who have relapsed, or for whom treatment regimens have stopped working after experiencing the three major drug classes, typically face poor survival. Despite recent innovation, new therapeutic approaches are still needed,” said Maria-Victoria Mateos, M.D., Ph.D., Consultant Physician in Haematology,
SCREEN Increases Efforts to Reduce the Environmental Impact of the Semiconductor Industry26.5.2022 06:30:00 CEST | Press release
SCREEN Semiconductor Solutions Co., Ltd. (SCREEN SPE), a subsidiary of SCREEN Holdings Co., Ltd., has announced it will increase its efforts to reduce the company’s environmental overall impact. The SCREEN Group is committed to both achieving a sustainable global society and to improving its sustainable value (social value) and has formulated a medium-term management plan titled Sustainable Value 2023 targeting these goals. The plan identifies specific issues in each of the environmental, social, and governance (ESG) fields. Concerning the environment, SCREEN is working to provide products and services that actively contribute to the reduction of ecological burden. Its efforts include improving the environmental performance of its products, reducing the effects of its business activities on climate change, promoting effective utilization of water resources, increasing recycling of products and parts, and helping to preserve biodiversity. Concretely, SCREEN SPE seeks to reduce the impac
Lenovo Group: Full Year Financial Results 2021/2226.5.2022 06:19:00 CEST | Press release
Lenovo Group (HKSE: 992) (ADR: LNVGY) today announced record fiscal year results for the Group, with historic highs for both profit and revenue. Annual net income reached the US$2 billion mark, up 72% year on year, with revenue growing by US$10 billion for the second year running to over US$71 billion. All main business groups were profitable for the full fiscal year - with strong growth momentum in mobile, infrastructure, and solutions and services businesses. Lenovo successfully overcame macro-environmental challenges and demonstrated both agility and resilience as it navigated industry-wide supply shortages, pandemic disruption, geopolitical uncertainties, and higher inflation to deliver a record year. The digital and intelligent transformation trend continues to accelerate, presenting the Group with strong growth opportunities. More than 50% of companies now have digitalization as part of their corporate strategy, up from just over one third two years ago. The hybrid work model is
Exscientia Business Update for First Quarter 202225.5.2022 22:01:00 CEST | Press release
Exscientia plc (Nasdaq: EXAI) This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220525005906/en/ Recent advancements in the Company’s pipeline, collaborations, and operations, as well as financial results for the first quarter 2022, are summarised below. In addition, Exscientia will host a conference call Thursday, May 26 at 1:30 p.m. BST / 8:30 a.m. ET to provide an overview of the Company's precision medicine platform. "We started 2022 by commencing a groundbreaking collaboration with Sanofi to develop a pipeline of AI-designed medicines utilising the breadth of our end-to-end platform of AI-driven capabilities from target prioritisation, to drug engineering and patient selection. At this year's American Association of Cancer Research (AACR) Annual Meeting, we highlighted our advancements in this area, including how AI-enabled drug design can help create drug candidates for challenging targets in oncology. In addition, we sho